Product Description
for the prevention of Major Adverse Kidney Events
Mechanisms of Action: p53 Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Quark
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Kidney Injury|Brain Death|Heart Transplant|Kidney Transplant|Renal Transplant
Phase 2: Acute Kidney Injury|Kidney Transplant|Renal Transplant|Heart Transplant
Phase 1: Acute Kidney Injury|Kidney Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00683553 |
QRK.004 | P1 |
Terminated |
Acute Kidney Injury|Kidney Diseases |
2010-05-01 |
2019-03-18 |
Treatments |
|
2015-003113-15 |
QPI-1002 Phase 2 AKI | P2 |
Completed |
Heart Transplant|Kidney Transplant|Acute Kidney Injury |
2018-03-05 |
2022-03-13 |
Treatments |
|
NCT02610283 |
QRK209 | P2 |
Completed |
Acute Kidney Injury |
2018-02-01 |
2019-03-20 |
Treatments |
|
2010-020989-20 |
I5NP Prophylaxis of Delayed Graft Function in Kidney Transplant | P2 |
Completed |
Renal Transplant |
2015-01-26 |
2022-03-13 |
Treatments |
|
NCT00802347 |
QRK.006 | P2 |
Completed |
Kidney Transplant |
2013-11-01 |
2019-03-18 |
||
2018-000757-49 |
QPI-1002 Phase 3 AKI | P3 |
Terminated |
Heart Transplant|Acute Kidney Injury|Kidney Transplant |
2021-04-01 |
2022-03-13 |
Treatments |
|
NCT03510897 |
QRK309 | P3 |
Terminated |
Acute Kidney Injury |
2020-10-14 |
14% |
2021-07-17 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
2015-003078-33 |
QPI-1002 Phase 3 DGF | P3 |
Completed |
Renal Transplant |
2019-02-22 |
2025-07-01 |
Treatments |
|
NCT02610296 |
ReGIFT | P3 |
Completed |
Kidney Transplant|Brain Death |
2018-06-28 |
22% |
2019-08-10 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/15/2024 |
News Article |
RNAi Therapeutics Market Size Expected to Reach USD 4.28 Bn by 2033 |
|
10/14/2021 |
News Article |
Acute Kidney Injury Treatment Market to Surpass US$ 3,031.6 Million by 2028, Says Coherent Market Insights (CMI) |
|
07/26/2021 |
News Article |
Acute Kidney Injury (AKI) Market Insight, Epidemiology and Market Forecast Report 2021-2030 - ResearchAndMarkets.com |
|
04/30/2020 |
News Article |
Acute Kidney Injury (AKI) Market Study, 2017-2030 - Featuring Emerging Drugs EA-230, bRESCAP, ANG-3777 (BB3), Teprasiran (QPI-1002) and ASP1128 |